News
AVCNF
0.089
+9.09%
0.007
Weekly Report: what happened at AVCNF last week (0706-0710)?
Weekly Report · 17h ago
Weekly Report: what happened at AVCNF last week (0629-0703)?
Weekly Report · 07/06 09:40
Avicanna strengthens leadership; promotes Nick Hilborn to CFO role
Seeking Alpha · 06/30 21:56
Avicanna promotes Nick Hilborn to CFO
PUBT · 06/30 21:30
AVICANNA ANNOUNCES PROMOTION OF NICK HILBORN CPA CA TO CHIEF FINANCIAL OFFICER
Reuters · 06/30 21:30
Weekly Report: what happened at AVCNF last week (0622-0626)?
Weekly Report · 06/29 09:37
Weekly Report: what happened at AVCNF last week (0615-0619)?
Weekly Report · 06/22 09:42
Splash Beverage Group invests CDN$ 300,000 in Avicanna private placement
PUBT · 06/15 12:32
Weekly Report: what happened at AVCNF last week (0608-0612)?
Weekly Report · 06/15 09:43
AVICANNA ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT
Reuters · 06/12 21:30
Splash Beverage invests $217,479.24 in Avicanna private placement, buys 2 million shares and 1 million warrants
PUBT · 06/12 21:01
Weekly Report: what happened at AVCNF last week (0601-0605)?
Weekly Report · 06/08 09:40
Weekly Report: what happened at AVCNF last week (0525-0529)?
Weekly Report · 06/01 09:43
Weekly Report: what happened at AVCNF last week (0518-0522)?
Weekly Report · 05/25 09:44
Weekly Report: what happened at AVCNF last week (0511-0515)?
Weekly Report · 05/18 09:44
Avicanna Inc. reports Q1 results
Seeking Alpha · 05/15 13:03
Canada's Avicanna Q1 revenue rises 6% to record high on commercial growth
Reuters · 05/14 11:39
AVICANNA REPORTS Q1 2026 FINANCIAL STATEMENTS
Reuters · 05/14 11:30
AVICANNA Q1 REVENUE CAD 6.68 MILLION
Reuters · 05/14 11:30
Weekly Report: what happened at AVCNF last week (0504-0508)?
Weekly Report · 05/11 09:42
More
Webull provides a variety of real-time AVCNF stock news. You can receive the latest news about Avicanna through multiple platforms. This information may help you make smarter investment decisions.
About AVCNF
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.